Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy

May 12, 2017

Sangamo Therapeutics, Inc. and Pfizer Inc. recently announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo’s four lead product candidates, which Sangamo expects will enter the clinic this quarter. Click here to read the full press release from Sangamo Therapeutics.

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.